ArticleCancers2020
Novel Treatment Strategies for Glioblastoma.
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Glioblastoma research on zebrafish xenograft models: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Pooled it
- Healthy dietary patterns, foods, and risk of glioma: A systematic review and meta-analysis of observational studies.Frontiers in nutrition · 2022Pooled it
- Integrated transcriptomic network analysis reveals shared immunogenomic regulators between glioma and type 2 diabetes, highlighting VCAN as a prominent marker.Scientific reports · 2026Article
- Advancements in Drug Delivery Systems in Glioblastoma Therapy.International journal of molecular sciences · 2026Review
- Resveratrol and AG490 Overcome Glioblastoma Cells' Resistance to Monotherapy by Inhibiting JAK2/STAT3 Signalling Pathway.Cancers · 2026Article
- Isorhamnetin from Astragalus membranaceus exerts anti-glioma effects via PI3K/Akt signaling pathway.American journal of cancer research · 2026Article
- {ZnMolecules (Basel, Switzerland) · 2026Article
- Clinical application of boron neutron capture therapy for cancer treatment: A systematic review.Precision radiation oncology · 2025Review
- VH032 suppresses glioma proliferation by inhibiting the VHL/HIF-1α/VEGF pathway.Biochemistry and biophysics reports · 2025Article
- Nanomedicine-Enhanced Radiotherapy for Glioblastoma: Advances in Targeted Therapy and Adaptive Treatment Strategies.Pharmaceutics · 2025Review
- The Small Molecules of Plant Origin with Anti-Glioma Activity.International journal of molecular sciences · 2025Review
- Anticancer potential of natural bioactive compounds saponins in glioblastoma multiforme.Frontiers in pharmacology · 2025Review
- Blood-tumor barrier in focus - investigation of glioblastoma-induced effects on the blood-brain barrier.Journal of neuro-oncology · 2024Article
- Complex Diagnostic Challenges in Glioblastoma: The Role ofPharmaceuticals (Basel, Switzerland) · 2024Review
- Toxicity profiles of immune checkpoint inhibitors in nervous system cancer: a comprehensive disproportionality analysis using FDA adverse event reporting system.Clinical and experimental medicine · 2024Article
- An improved F98 glioblastoma rat model to evaluate novel treatment strategies incorporating the standard of care.PloS one · 2024Article
- Paromomycin targets HDAC1-mediated SUMOylation and IGF1R translocation in glioblastoma.Frontiers in pharmacology · 2024Article
- U3 snoRNA-mediated degradation of ZBTB7A regulates aerobic glycolysis in isocitrate dehydrogenase 1 wild-type glioblastoma cells.CNS neuroscience & therapeutics · 2023Article
- Efficacy of TTFields in high-grade gliomas: a protocol for systematic review and meta-analysis.BMJ open · 2023Article
- Design, synthesis, and biological activity of dual monoamine oxidase A and heat shock protein 90 inhibitors, N-Methylpropargylamine-conjugated 4-isopropylresorcinol for glioblastoma.European journal of medicinal chemistry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is the most common primary central nervous system tumor in adults. It is a highly invasive disease, making it difficult to achieve a complete surgical resection, resulting in poor prognosis with a median survival of 12-15 months after diagnosis, and less than 5% of patients survive more than 5 years. Surgical, instrument technology, diagnostic and radio/chemotherapeutic strategies have slowly evolved over time, but this has not translated into significant increases in patient survival. The current standard of care for GBM patients involving surgery, radiotherapy, and concomitant chemotherapy temozolomide (known as the Stupp protocol), has only provided a modest increase of 2.5 months in median survival, since the landmark publication in 2005. There has been considerable effort in recent years to increase our knowledge of the molecular landscape of GBM through advances in technology such as next-generation sequencing, which has led to the stratification of the disease into several genetic subtypes. Current treatments are far from satisfactory, and studies investigating acquired/inherent resistance to current therapies, restricted drug delivery, inter/intra-tumoral heterogeneity, drug repurposing and a tumor immune-evasive environment have been the focus of intense research over recent years. While the clinical advancement of GBM therapeutics has seen limited progression compared to other cancers, developments in novel treatment strategies that are being investigated are displaying encouraging signs for combating this disease. This aim of this editorial is to provide a brief overview of a select number of these novel therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.